KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Accumulated Expenses (2018 - 2025)

Historic Accumulated Expenses for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $31.8 million.

  • Castle Biosciences' Accumulated Expenses rose 1478.39% to $31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.8 million, marking a year-over-year increase of 1478.39%. This contributed to the annual value of $32.6 million for FY2024, which is 1247.19% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Accumulated Expenses is $31.8 million, which was up 1478.39% from $25.0 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Accumulated Expenses ranged from a high of $32.6 million in Q4 2024 and a low of $5.2 million during Q1 2021
  • Moreover, its 5-year median value for Accumulated Expenses was $17.9 million (2025), whereas its average is $19.0 million.
  • In the last 5 years, Castle Biosciences' Accumulated Expenses skyrocketed by 9074.6% in 2021 and then surged by 1247.19% in 2024.
  • Quarter analysis of 5 years shows Castle Biosciences' Accumulated Expenses stood at $15.5 million in 2021, then soared by 57.32% to $24.4 million in 2022, then rose by 18.83% to $28.9 million in 2023, then rose by 12.47% to $32.6 million in 2024, then fell by 2.43% to $31.8 million in 2025.
  • Its Accumulated Expenses stands at $31.8 million for Q3 2025, versus $25.0 million for Q2 2025 and $17.9 million for Q1 2025.